Philip L Felgner Selected Research

Subunit Vaccines

1/2021	Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population.
1/2021	Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis.
1/2017	Distinct antibody responses of patients with mild and severe leptospirosis determined by whole proteome microarray analysis.
1/2016	A next-generation proteome array for Schistosoma mansoni.
10/2015	A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases.
3/2014	An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas.
3/2012	Identification of a common immune signature in murine and human systemic Salmonellosis.
1/2012	Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development.
7/2011	Identification of potential serodiagnostic and subunit vaccine antigens by antibody profiling of toxoplasmosis cases in Turkey.
2/2010	Defining the humoral immune response to infectious agents using high-density protein microarrays.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip L Felgner Research Topics

Disease

58	Infections 01/2022 - 01/2005
40	Malaria 09/2021 - 07/2006
12	COVID-19 01/2022 - 01/2020
9	Communicable Diseases (Infectious Diseases) 01/2021 - 02/2010
7	Schistosomiasis (Bilharziasis) 11/2021 - 01/2010
6	Vaccinia 08/2014 - 01/2005
5	Reinfection 01/2021 - 03/2014
5	Persistent Infection 01/2016 - 08/2010
5	Melioidosis 07/2011 - 01/2009
4	Human Influenza (Influenza) 01/2022 - 12/2018
4	Leptospirosis 01/2021 - 01/2013
4	Q Fever (Fever, Q) 01/2021 - 12/2008
4	Typhoid Fever (Typhoid) 01/2017 - 01/2013
4	Brucellosis (Malta Fever) 01/2014 - 05/2010
3	Pneumonia (Pneumonitis) 01/2022 - 01/2011
3	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2018 - 07/2006
3	Tularemia 01/2016 - 06/2007
3	Toxoplasmosis 05/2015 - 02/2007
3	Tuberculosis (Tuberculoses) 09/2012 - 08/2010
2	Schistosomiasis haematobia (Schistosomiasis haematobium) 11/2021 - 01/2021
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2020
2	Bacteremia 01/2021 - 03/2012
2	Neoplasms (Cancer) 01/2021 - 01/2015
2	Fever (Fevers) 03/2016 - 03/2014
2	Bites and Stings (Sting) 03/2016 - 12/2013
2	Pemphigus (Pemphigus Vulgaris) 01/2013 - 02/2011
2	Neglected Diseases 01/2013 - 01/2009
1	Bacillary Dysentery (Shigellosis) 01/2021
1	Poliomyelitis (Polio) 01/2021
1	Papilloma (Papillomatosis) 01/2021
1	Chronic Traumatic Encephalopathy 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Tauopathies 01/2020
1	Virus Diseases (Viral Diseases) 12/2018
1	Cerebral Malaria 01/2018
1	Inflammation (Inflammations) 01/2017
1	Cholera 01/2017
1	Schistosomiasis japonica 01/2016

Drug/Important Bio-Agent (IBA)

73	AntigensIBA 11/2021 - 01/2005
65	Proteins (Proteins, Gene)FDA Link 09/2021 - 09/2005
42	VaccinesIBA 01/2022 - 01/2005
37	AntibodiesIBA 11/2021 - 10/2007
19	Immunoglobulin G (IgG)IBA 11/2021 - 07/2011
19	ProteomeIBA 01/2021 - 01/2005
11	Subunit VaccinesIBA 01/2021 - 01/2009
9	Biomarkers (Surrogate Marker)IBA 11/2021 - 08/2010
9	Immunoglobulin M (IgM)IBA 01/2018 - 07/2011
8	EpitopesIBA 03/2021 - 06/2008
6	Immunoglobulin A (IgA)IBA 09/2021 - 01/2016
5	Surface Antigens (Surface Antigen)IBA 01/2021 - 11/2011
5	Peptides (Polypeptides)IBA 01/2020 - 07/2011
4	Malaria VaccinesIBA 10/2017 - 01/2015
3	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 09/2021 - 12/2015
3	EnzymesIBA 01/2021 - 01/2014
3	Hemolysin Proteins (Hemolysins)IBA 06/2017 - 03/2014
3	Immunodominant EpitopesIBA 08/2014 - 05/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2011 - 02/2007
2	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 01/2019
2	Neutralizing AntibodiesIBA 01/2022 - 09/2021
2	Praziquantel (Biltricide)FDA Link 01/2021 - 01/2015
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2015
2	ImmunosorbentsIBA 01/2021 - 03/2014
2	NucleoproteinsIBA 01/2021 - 05/2020
2	Chloroquine (Aralen)FDA LinkGeneric 01/2019 - 12/2013
2	Collodion (Nitrocellulose)IBA 01/2019 - 12/2008
2	LipopolysaccharidesIBA 06/2017 - 01/2016
2	Polysaccharides (Glycans)IBA 01/2017 - 01/2009
2	CytokinesIBA 10/2015 - 07/2011
2	Recombinant ProteinsIBA 05/2015 - 01/2012
2	Interferon-gamma (Interferon, gamma)IBA 01/2014 - 07/2011
2	AutoantibodiesIBA 01/2013 - 02/2011
2	Immune Sera (Antisera)IBA 03/2012 - 01/2010
2	Smallpox Vaccine (Vaccine, Smallpox)FDA Link 05/2007 - 09/2005
1	amotosalenIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Messenger RNA (mRNA)IBA 11/2021
1	Immunologic Factors (Immunomodulators)IBA 09/2021
1	Combined VaccinesIBA 01/2021
1	FCPAIBA 01/2021
1	AC133 AntigenIBA 01/2021
1	Disinfectants (Biocides)IBA 01/2021
1	Single-Chain AntibodiesIBA 01/2020
1	Tissue ExtractsIBA 01/2020
1	Cysteine (L-Cysteine)FDA Link 08/2019
1	Indicators and Reagents (Reagents)IBA 08/2019
1	Neuraminidase (Sialidase)IBA 01/2019
1	FlagellinIBA 01/2018
1	Type V Secretion SystemsIBA 01/2018
1	pertactin FDA Link 01/2018
1	endoxo-delta(4)-tetrahydrophthalic acidIBA 01/2018
1	2- (N- phenethyl- N- propyl)amino- 5- hydroxytetralinIBA 01/2017
1	AllergensIBA 01/2016
1	Antimalarials (Antimalarial Agents)IBA 11/2015
1	Immunoglobulins (Immunoglobulin)IBA 09/2015
1	Inosine Diphosphate (IDP)IBA 07/2015

Therapy/Procedure

5	Therapeutics 09/2021 - 01/2011
3	Immunotherapy 01/2022 - 10/2007
2	Mass Drug Administration 01/2017 - 03/2014
1	Chemoprevention 01/2019